<?xml version="1.0" encoding="UTF-8"?>
<document id="DrugDDI.d28" origId="Anakinra"><sentence id="DrugDDI.d28.s0" origId="s0" text="No drug-drug interaction studies in human subjects have been conducted."/><sentence id="DrugDDI.d28.s1" origId="s1" text="Toxicologic and toxicokinetic studies in rats did not demonstrate any alterations in the clearance or toxicologic profile of either methotrexate or Kineret? when the two agents were administered together."><entity id="DrugDDI.d28.s1.e0" origId="s1.p19" charOffset="132-144" type="drug" text="methotrexate"/></sentence><sentence id="DrugDDI.d28.s2" origId="s2" text="In a study in which patients with active RA were treated for up to 24 weeks with concurrent Kineret? and etanercept therapy, a 7% rate of serious infections was observed, which was higher than that observed with etanercept alone (0%)."><entity id="DrugDDI.d28.s2.e0" origId="s2.p36" charOffset="105-115" type="drug" text="etanercept"/><entity id="DrugDDI.d28.s2.e1" origId="s2.p48" charOffset="212-222" type="drug" text="etanercept"/><pair id="DrugDDI.d28.s2.p0" e1="DrugDDI.d28.s2.e0" e2="DrugDDI.d28.s2.e1" interaction="?"/></sentence><sentence id="DrugDDI.d28.s3" origId="s3" text="Two percent of patients treated concurrently with Kineret? and etanercept developed neutropenia (ANC  1 x 109/L)."><entity id="DrugDDI.d28.s3.e0" origId="s3.p58" charOffset="63-73" type="drug" text="etanercept"/><entity id="DrugDDI.d28.s3.e1" origId="s3.p62" charOffset="97-112" type="drug" text="ANC  1 x 109/L"/><pair id="DrugDDI.d28.s3.p0" e1="DrugDDI.d28.s3.e0" e2="DrugDDI.d28.s3.e1" interaction="?"/></sentence></document>